Cognizant’s (CTSH.Q) shared investigator platform (SIP) has reached over 100,00 new users in 84 countries, according to a press release.

The software as a service platform has become important to progressing clinical trials, as social distancing has made face to face collaboration increasingly difficult as many of the companies using the service to push COVID-19 therapies through virtual clinical trial processes.

“The COVID-19 pandemic has brought the processes of healthcare and life sciences firms to the forefront of global attention as the need to leverage advanced technologies for faster results and better care is paramount. Our Shared Investigator Platform seamlessly enables communication and collaboration in clinical trials in areas such as site activation, document exchange, and safety notifications. Our milestone of 100,000 users across 84 countries is a testament to the value we are providing to those diligently working to accelerate innovative, effective treatments to patients in need,” said Srinivas Shankar, senior vice president and global head for Cognizant’s Life Sciences business.

Cognizant’s platform links clinical trial sponsors and medical professionals through automation and remote access technology, increasing the efficiency of drug trials and the speed by which the products are brought to market. Since its inception, seven of the world’s largest biopharmaceutical companies have come onboard to use the company’s platform.

The platform was launched in 2016 through the combined efforts of Cognizant and TransCelerate, a consortium of biopharmaceutical companies. The platform is used at over 19,000 trial-ready sites by medical and life sciences professionals. It reduces administrative difficulties that can impede development and testing of clinical therapies.

The word on Twitter has this company on an eight day run.


—Joseph Morton

Written By:

Joseph Morton

Joseph is a Vancouver-based author and journalist with both a communications degree and journalism diploma (and a few novels) under his belt. His joie de vivre is to spin difficult technical topics into more human-centric narratives. Buy him a coffee and he'll talk your ear off for hours about privacy issues, blockchain, cryptocurrency and martial arts. Don't talk to him if you're either a tomato, a bully, or if you're not a fan of either 1984 or Tender is the Night. No. You can still talk to him. Just be prepared to be told why you're wrong.

More By This Author
biopharmaceutical companies
0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments